• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Gastrointestinal Pipeline Drugs

Article

Credits: 1.0 contact hours (0.10 CEUs)

Michael Marlan Mohundro, PharmD, Director of Pharmacy, Our Lady of the Lake Regional Medical Center

Brice Labruzzo Mohundro, PharmD, Assistant Professor, University of Louisiana at Monroe College of Pharmacy—Baton Rouge Campus

Educational Objectives

After completing this activity, participants should be able to:

  • Identify and compare mechanisms of action, safety, tolerability, and efficacy profiles of emerging therapies for common gastrointestinal (GI) disorders
  • Recognize the roles of emerging therapies for the treatment of specific GI disorders

Target Audience: This activity is intended for pharmacists—in the community, health systems, or other environments—who treat patients with GI disorders, or any healthcare practitioners who are interested in the availability of new drugs to treat GI disorders.

Related Videos
Leslie Fish, PharmD.
Ronesh Sinha, MD
Adam Colborn, JD
Beau Raymond, MD
Judith Alberto, MHA, RPh, BCOP, director of clinical initiatives, Community Oncology Alliance
Yuqian Liu, PharmD
Jenny Craven, PharmaD, BCPS
Kimberly Westrich, MA
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Sarah Bajorek, PhD, BCACP, MBA.
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.